BioNexus Gene Lab Corp Common stock - Asset Resilience Ratio
BioNexus Gene Lab Corp Common stock (BGLC) has an Asset Resilience Ratio of 22.85% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of BioNexus Gene Lab Corp Common stock to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how BioNexus Gene Lab Corp Common stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BGLC current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down BioNexus Gene Lab Corp Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BGLC long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.74 Million | 22.85% |
| Total Liquid Assets | $1.74 Million | 22.85% |
Asset Resilience Insights
- Good Liquidity Position: BioNexus Gene Lab Corp Common stock maintains a healthy 22.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
BioNexus Gene Lab Corp Common stock Industry Peers by Asset Resilience Ratio
Compare BioNexus Gene Lab Corp Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
China Minmetals Rare Earth Co Ltd
SHE:000831 |
Specialty Chemicals | 0.91% |
|
Orica Ltd
AU:ORI |
Specialty Chemicals | 7.51% |
|
Novoray Corporation
SHG:688300 |
Specialty Chemicals | 9.73% |
|
Jiangsu Sidike New Materials Sci Te
SHE:300806 |
Specialty Chemicals | 0.05% |
|
Zhejiang Longsheng Group Co Ltd
SHG:600352 |
Specialty Chemicals | 0.80% |
|
Ningbo Shanshan Co Ltd
SHG:600884 |
Specialty Chemicals | 0.00% |
|
Hengyi Petrochemical Co Ltd
SHE:000703 |
Specialty Chemicals | 0.16% |
|
SKC Co. Ltd
KO:011790 |
Specialty Chemicals | 3.90% |
Annual Asset Resilience Ratio for BioNexus Gene Lab Corp Common stock (2017–2024)
The table below shows the annual Asset Resilience Ratio data for BioNexus Gene Lab Corp Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.78% | $2.79 Million | $10.43 Million | -2.22pp |
| 2023-12-31 | 29.00% | $3.31 Million | $11.40 Million | +11.75pp |
| 2022-12-31 | 17.24% | $1.51 Million | $8.74 Million | +1.10pp |
| 2021-12-31 | 16.14% | $1.55 Million | $9.57 Million | -4.50pp |
| 2020-12-31 | 20.64% | $2.09 Million | $10.12 Million | -19.40pp |
| 2019-12-31 | 40.04% | $493.04K | $1.23 Million | +3.67pp |
| 2018-12-31 | 36.38% | $601.00K | $1.65 Million | +36.18pp |
| 2017-12-31 | 0.20% | $2.55K | $1.27 Million | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more